Harlow Alyssa F, Hendricks Peter S, Leventhal Adam M, Barrington-Trimis Jessica L
Department of Population and Public Health Sciences, University of Southern California Keck School of Medicine, Los Angeles, CA, USA.
Institute for Addiction Science, University of Southern California, Los Angeles, CA, USA.
J Psychoactive Drugs. 2024 Feb 10:1-12. doi: 10.1080/02791072.2024.2313684.
Despite common depictions in the media, there is little scientific evidence on microdosing psychedelic drugs. We assessed awareness, prevalence, and dosing practices of microdosing psychedelic drugs among young adults 18-22 years old from Southern California (2018-2019). We examined whether sociodemographic factors, personality traits, mental health, or other substance use behaviors were correlated with having ever microdosed. Among 2,396 participants, 293 (12%) had heard of microdosing and 74 (3%) ever microdosed. Among those who had heard of microdosing, 79% correctly defined microdosing as taking an amount of a psychedelic much lower than a standard dose, whereas 15% misperceived microdosing as a standard psychedelic dose. Psilocybin was the most common drug ever microdosed (70%), followed by lysergic acid diethylamide (LSD, 57%). Among those who ever microdosed, ~18% reported using psychoactive doses far higher than would be generally considered a microdose. White race, male/masculine gender identity, bisexual identity, past 6-month other drug use, greater attention deficit/hyperactivity disorder symptoms, mindfulness, and sensation-seeking were positively associated with having ever microdosed in multivariable models. Young adult microdosing merits further attention from scientific and public health professionals to help prevent misperceptions and potential adverse consequences as well as explore its potential therapeutic applications.
尽管媒体有常见的描述,但关于微剂量使用迷幻药物的科学证据很少。我们评估了南加州18 - 22岁年轻人(2018 - 2019年)中微剂量使用迷幻药物的知晓情况、流行率和用药习惯。我们研究了社会人口学因素、人格特质、心理健康或其他物质使用行为是否与曾经进行微剂量用药相关。在2396名参与者中,293人(12%)听说过微剂量用药,74人(3%)曾经进行过微剂量用药。在那些听说过微剂量用药的人中,79%正确地将微剂量用药定义为服用远低于标准剂量的迷幻药物,而15%错误地将微剂量用药理解为标准的迷幻药物剂量。裸盖菇素是最常被微剂量使用的药物(70%),其次是麦角酸二乙酰胺(LSD,57%)。在那些曾经进行微剂量用药的人中,约18%报告使用的精神活性剂量远高于通常被认为是微剂量的水平。在多变量模型中,白人、男性/男性性别认同、双性恋认同、过去6个月使用其他药物、更多的注意力缺陷/多动障碍症状、正念和寻求刺激与曾经进行微剂量用药呈正相关。年轻成年人的微剂量用药值得科学和公共卫生专业人员进一步关注,以帮助防止误解和潜在的不良后果,并探索其潜在的治疗应用。